Prenetics Global (NASDAQ:PRE) Posts Earnings Results

Key Points

• Prenetics Global reported a quarterly loss of ($0.82) EPS, with a negative net margin of 115.91% and a negative return on equity of 28.07%.
• The company's stock price increased to $10.03, significantly above its 52-week low of $3.09 and close to its high of $11.99.
• Prenetics received a rating upgrade to "hold" from Wall Street Zen, with an average analyst rating of "Buy" and a consensus target price of $9.00.

Prenetics Global (NASDAQ:PRE - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.82) earnings per share for the quarter, Zacks reports. The firm had revenue of $17.68 million for the quarter. Prenetics Global had a negative net margin of 87.92% and a negative return on equity of 31.05%. Prenetics Global updated its FY 2025 guidance to EPS.

Prenetics Global Trading Up 13.0%

Shares of PRE stock traded up $1.23 during trading hours on Wednesday, reaching $10.72. The company's stock had a trading volume of 113,893 shares, compared to its average volume of 35,992. The stock has a market capitalization of $139.20 million, a P/E ratio of -2.69 and a beta of 0.15. Prenetics Global has a one year low of $3.09 and a one year high of $11.99. The firm's fifty day simple moving average is $8.09 and its 200 day simple moving average is $6.78.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Prenetics Global to a "hold" rating in a report on Saturday, July 5th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $9.00.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.